Pharmacy and Therapeutics Update
|
|
- Prudence Wheeler
- 5 years ago
- Views:
Transcription
1 Pharmacy and Therapeutics Update Summer 2017 Highlights of recent drug policy revisions, as well as any new drug policies approved by Prevea360 Health Plan s Medical Policy Committee, are shown below. NOTE: All changes to the policies may not be reflected in the written highlights below. It is encouraged all prescribers review the current policies. ALL DRUGS that have written Prevea360 Health Plan policies MUST BE PRIOR AUTHORIZED by sending requests to Navitus, unless otherwise noted in the policy. Please note that most drugs require specialists to prescribe and request authorization. We encourage all prescribers to review the current policies. Policies regarding medications may be found on prevea360.com by searching drug policies. Please note that the name of the drug (either brand or generic name) must be spelled completely and correctly when using the search bar. New Drug Policies LUMIGAN (bimatoprost ophthalmic 0.03 percent) PA9934 LUMIGAN requires prior authorization through Navitus and is considered medically appropriate when the patient has failed (at least a one-month trial) taking latanoprost and Travatan Z. LUMIGAN requires prior authorization through Navitus and must be prescribed by or in consultation with ophthalmology or optometry specialists.
2 WELCHOL (colesevelam) PA9935 WELCHOL requires prior authorization through Navitus and is considered medically appropriate when the patient has a clinical diagnosis of familial hypercholesterolemia; and failed (at least a one-month trial) with cholestyramine or colestipol. WELCHOL requires prior authorization through Navitus and must be prescribed by or in consultation with a cardiology specialist. PIROXICAM CAPSULES PA9936 PIROXICAM CAPSULES requires prior authorization through Navitus and is considered medically appropriate when the patient has a clinical diagnosis of a spondylo-arthropathy and has failed (at least a one-month trial of) meloxicam. PIROXICAM CAPSULES requires prior authorization through Navitus and must be prescribed by or in consultation with rheumatology specialists. STIVARGA (regorafenib) PA9937 STIVARGA requires prior authorization through Navitus and is considered medically appropriate when the patient has a clinical diagnosis of locally advanced, unresectable, or metastatic GI stromal tumor or metastatic colorectal cancer. STIVARGA requires prior authorization through Navitus and must be prescribed by or in consultation with oncology specialists. CHANGES TO DRUG POLICY NUVIGIL (armodafanil) PA9876 Refractory Attention Deficit Hyperactivity Disorder (ADHD) in patients who have failed one formulary stimulant is now a covered indication. NUVIGIL requires prior authorization through Navitus. PERJETA (pertuzumab) MP9438 Must be prescribed by, or in consultation with, an oncologist or hematologist with prior authorization through Navitus. Also added NCCN categories for off label uses in oncology, and authorization duration limits. ABILIFY MAINTENA (aripiprazole) MP9456 Must be prescribed by or in consultation with a psychiatrist with prior authorization through Navitus. Addition of initial and renewal authorization duration limits. PROMACTA (eltrombopag) PA9867 Addition of initial and renewal authorization duration limits. TRINTELLIX (Vortioxetine) PA9902 Must be prescribed by, or in consultation with, a psychiatrist with prior authorization through Navitus. 2
3 RITUXAN (rituximab) PA9847 Effective September 1, 2017, RITUXAN will require prior authorization through Navitus and is restricted to rheumatology, transplant, hematology, neurology or oncology specialists. Additional indications RITUXAN is covered for, include chronic graft versus host disease, neurolyelitis optica, post transplant lumphoproliferative disorder, thrombotic thrombocytopenic purpura, immune or idiopathic thrombocytopenic purpura, and autoimmune hemolytic anemia. Also added NCCN categories for off label uses in oncology and authorization duration limits. REMICADE (infliximab) INFLECTRA (infliximab-dyyb) MP9231 REMICADE is restricted to dermatology, rheumatology and gastroenterology specialists with prior authorization through Navitus. Prior authorization is required for all prescribers. Please review the policy. GAZYVA (obinutuzumab) MP9451 GAZYVA is restricted to oncology specialists with prior authorization through Navitus. Also added NCCN categories for off label uses in oncology, and authorization duration limits. CIMZIA (certolizumab pegol) PA9875 CIMZIA requires prior authorization through Navitus and is restricted to rheumatology and gastroenterology specialists. A failed trial of HUMIRA and ENBREL is required for patients with early severe rheumatoid arthritis, a diagnosis of rheumatoid arthritis longer than three years, active psoriatic arthritis and active ankylosing spondylitis. A failed trial of HUMIRA is required for patients with moderate to severe Crohn s disease. Also added language that CIMZIA may not be prescribed in combination with other biologic DMARDs, in patients with tuberculosis or other serious infections, or in those patients without a tuberculin skin test to evaluate for latent tuberculosis prior to initiating. Please review the policy. SIMPONI and SIMPONI ARIA (golimumab) PA9874 SIMPONI requires prior authorization through Navitus and is restricted to rheumatology or gastroenterology specialists. Requires failed trials (at least one month each) of Humira and Enbrel for Rheumatoid Arthritis, Peripheral Ankylosing Spondylitis and Psoriatic Arthritis. Requires failed trial of Humira for Ulcerative Colitis. SIMPONI ARIA does not require prior authorization. Please review the policy. ENBREL (etanercept) PA9716 Added quantity limits and specialty pharmacy requirement statement, and additional criteria language for those with moderate to severe plaque psoriasis. Please review the policy. 3
4 ORENCIA (abatacept) SQ FORMULATION PA9846 ORENCIA SQ must be prescribed by rheumatology specialists with prior authorization through Navitus. Added language that it may not be prescribed in combination with other biologic DMARDs, in patients with tuberculosis or other serious infections, or in those patients without a tuberculin skin test to evaluate for latent tuberculosis prior to initiating. Please review the policy. ORENCIA (abatacept) IV FORMULATION MP9457 ORENCIA IV must be prescribed by rheumatology specialists with prior authorization through Navitus. Clarified language surrounding failure of prior therapy, and added language that it may not be prescribed in combination with other biologic DMARDs, in patients with tuberculosis or other serious infections, or in those patients without a tuberculin skin test to evaluate for latent tuberculosis prior to initiating. Please review the policy. ACTEMRA (tocilizumab) IV FORMULATION MP9405 Clarified language surrounding failure of prior therapy, and Added language that it may not be prescribed in combination with other biologic DMARDs, in patients with tuberculosis or other serious infections, or in those patients without a tuberculin skin test to evaluate for latent tuberculosis prior to initiating. Please review the policy. XELJANZ (tofacitinib) PA9897 Clarified language surrounding failure of prior therapy. HUMIRA (adalimumab) PA9822 Panuveitis is now a covered indication for HUMIRA. HUMRIA must be prescribed by rheumatology (RA, JIA, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, or panuveitis), gastroenterology (Crohn s Disease and Ulcerative Colitis), dermatology (plaque psoriasis), or ophthomology (panuveitis) specialists with prior authorization through Navitus. Also added language to criteria for plaque psoriasis, Crohn s Disease, and panuveitis. Please review the policy. LEMTRADA (alemtuzumab) MP9468 LEMTRADA patients must have a negative HIV lab result and patients and providers must be enrolled in the LEMTRADA REMS program. LEMTRADA requires prior authorization through Navitus and must be prescribed by a neurology specialist. GILENYA (fingolimod) PA9922 Added requirement of discontinuation of current disease modifying therapy before initiating. 4
5 TYSABRI (natalizumab) PA9854 TYSABRI must be prescribed by a neurology (for relapsing, remitting multiple sclerosis) or gastroenterology (for moderate to severe Crohn s Disease) specialists with prior authorization through Navitus. Please review the policy. LYRICA (pregabalin) PA9845 Changed dose titration requirements for gabapentin, removed requirement of amitriptyline trial, added requirement of duloxetine trial. ZINBRYTA (daclizumab) PA9930 ZINBRYTA requires prior authorization through Navitus and must be prescribed either in consultation with or by a neurology specialist. ZINBRYTA is contraindicated for patients with preexisting hepatic disease or hepatic impairment. The patient must also fulfill the ZINBRYTA REMS program requirements. FORMULARY CHANGES The following are formulary changes as a result of Pharmacy and Therapeutic Committee activity. Other changes to the formularies may be found by going to prevea360.com. Choose the Recent Formulary Changes for the selected formulary. Class Reviews Mesalamines Change Asacol HD, mesalamine DR and Delzicol from PB to NC. Change Apriso from NPB to PB. Keep Lialda at PB. (January 1, 2018) LAMAs Change Spiriva from PB to NC. Keep Incruse PB. (January 1, 2018) with QL. LAMA/LABAs Change Anoro from NC to preferred brand. Keep Stiolto to PB. Members who require a non-formulary agent may be presented as medical exceptions via the exception to coverage process. (January 1, 2018) with QL. 5
6 Constipation Change Linzess from NPB with PA to PB with PA (SS through an OTC product). Change Movantik from NC to PB with PA (SS through an OTC product). Change Relistor from PB with PA to NC. Change Amitiza from NC to NPB with PA for Exchange LOB if required for benchmarks. (January 1, 2018). Opioid Dependency Change Bunavail and Zubsolv from NC to PB. Change buprenorphine/naloxone tabs from NPG to NC (NDC block). Keep Suboxone film at PB. (January 1, 2018). All changes noted below will have the following effective date: Commercial new starts (May 1, 2017) providing a 90-day transition period for current users beginning May 1, PPIs Formulary agents: omeprazole caps and pantoprazole (PG), and First Omeprazole and Lansoprazole Suspensions (PB). Change lansoprazole and rabeprazole from PG to NC. Change Prevacid Solutab from PB to NC. Change Dexilant from NPB with ST to NC. All other products in this class to remain at their current tier. ACEs Formulary agents: Lisinopril, benazepril, lisinopril/hctz, enalapril/hctz will remain as PG, Epaned (enalapril solution) will remain at NPB with a PA. Change the following from PG to NC: Captopril, enalapril, fosinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, benazepril/hctz, captopril/hctz, fosinopril/hctz, moexipril/hctz, quinapril/hctz. ARBs Formulary agents: Losartan, irbesartan, losartan/hctz and valsartan/hctz will remain at PG. Valsartan will be NPG with a PA. Change valsartan from PG to non-pg with PA. Change irbesartan from PG to NC. Change candesartan, telmisartan, and candesartan/hctz from PB to NC. 6
7 Change Edarbi and Edarbyclor from NPB with ST to NC. Topical Steroids Unless otherwise noted, all other agents will remain at their current tier. Change from PG to NC: Betamethasone dip 0.05 percent ointment, Fluocinonide 0.05 percent cream, Fluocinonide 0.01 percent cream, Fluocinonide 0.05 percent ointment, Diflorasone ointment, Prednicarbate cream and ointment, Pramosone cream and ointment. Change from PB to NC: Desoximetasone 0.05 percent cream, Flurandrenolide. Change from PB with PA to NC: Clobetasol 0.05 percent cream and ointment, Clobetasol foam. Change from NPB to NC: Verdeso, Taclonex. Change from PB with PA to PB (no authorization required): Clobetasol E 0.05 percent cream, Clobetasol 0.05 percent solution. Ophthalmic Prostaglandins Lumigan will change from PB to NPB with PA. Criteria: Must be prescribed by ophthalmology or optometry, and failure of latanoprost and Travatan Z. Latanoprost (PG) and Travatan Z (PB) will remain formulary alternatives. Triptans Zolmitriptan tabs and ODT tabs will change from PB to NC. All other formulary alternatives will remain unchanged, including rizatriptan tabs and ODT tabs, sumatriptan nasal, tabs, and injection at PG, naratriptan at PB, and Alsuma injection, Sumavel Dosepro, and Zomig nasal (NPB). Bile Acid Sequestrants Welchol will change from PB to NPB with PA. Criteria: Prescribed by preventive cardiology, diagnosis of familial hypercholesterolemia and failed either cholestyramine or colestipol. H2 Blockers Cimetidine tabs and solution will change from PG to NC. Fluoxetine Tablets will change from PG to NC. Capsules and solution will remain at PG. Intranasal antihistamines Olopatadine will change from PB to NC. 7
8 NSAIDs Naproxen sodium 550 mg tab (Anaprox) will change from PB to NC. Piroxicam caps will change from PB to PB with PA. Criteria: Prescribed by rheumatology, treatment for spondylarthropathies and failure of meloxicam. Abbreviations: EGFR : Epidermal growth factor GIST: gastrointestinal stromal tumor HCTZ: hydrochlorothiazide KRAS: V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog mcrc: Metastatic colorectal cancer LABA: Long acting beta agonist LAMA: Long acting muscarinic antagonist LOB: Line of business NC: Not covered NPB: Non-preferred brand NPG: Non-preferred generic OTC: Over-the-counter PA: Prior authorization PB: Preferred brand PG: Preferred generic QL: Quantity limit SS: Single step ST: Step therapy VEGF: Vascular endothelial growth factor XOI: Xanthine oxidase inhibitor 8
Immune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationDrug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More information2018 Step Therapy Criteria
2018 Step Therapy Criteria ANGIOTENSIN RECEPTOR BLOCKERS... 2 ANTIDEPRESSANTS... 3 ANTIDEPRESSANTS, MISCELLANEOUS... 4 ANTIDEPRESSANTS, OTHER... 5 ANTIDIABETIC AGENTS... 6 ANTIGOUT AGENTS... 7 ANTIHYPERTENSIVE
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of
More informationCARE N CARE HEALTH PLAN
PPI DEXILANT CAPSULE DELAYED RELEASE 30 MG ORAL DEXILANT CAPSULE DELAYED RELEASE 60 MG ORAL Claim will pay automatically for Dexilant if enrollee has a paid claim for at least a 1 days supply of lansoprazole,
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationBiologics for Autoimmune Diseases
Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines
More informationASEBP and ARTA TARP Drugs and Reference Price by Categories
ASEBP Pantoprazole Sodium 40 mg (generic) $0.2016 ASEBP Dexlansoprazole 30 mg Dexlansoprazole 60 mg Esomeprazole 10 mg Esomeprazole 20 mg Esomeprazole 40 mg Lansoprazole 15 mg Lansoprazole 30 mg Omeprazole
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),
More informationSimponi / Simponi ARIA (golimumab)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationHEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria
GLP1-INSULIN XULTOPHY SOLUTION PEN- INJECTOR 100-3.6 UNIT-MG/ML Claim will pay automatically for Xultophy if enrollee has a paid claim for at least a one day supply for step level 1 agent (LANTUS, LEVEMIR,
More informationHEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria
GLP1-INSULIN XULTOPHY SOLUTION PEN- INJECTOR 100-3.6 UNIT-MG/ML HEALTHTEAM ADVANTAGE Claim will pay automatically for Xultophy if enrollee has a paid claim for at least a one day supply for step level
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationMedication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
More informationHEALTHTEAM ADVANTAGE PLAN 2017 Step Therapy Criteria Pending CMS Approval
ARISTADA - ARISTADA INJ 441MG/1.6 ARISTADA INJ 662MG/2.4 ARISTADA INJ 882MG/3.2 CLAIM WILL PAY AUTOMATICALLY FOR ARISTADA IF ENROLLEE HAS A PAID CLAIM FOR AT LEAST A 1 DAYS SUPPLY OF ABILIFY MAINTENA AND
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationBiologic Immunomodulators Prior Authorization with Quantity Limit Program Summary
Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationPharmacy Management Drug Policy
SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationMedication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
More informationCorporate Medical Policy
Corporate Medical Policy Infliximab, Infliximab-dyyb, Infliximab-abda File Name: Origination: Last CAP Review: Next CAP Review: Last Review: infliximab 5/2002 2/2018 2/2019 7/2018 Description of Procedure
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationRITUXAN (rituximab and hyaluronidase human)
Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria
More informationBRINTELLIX. Step Therapy Criteria HealthTeam Advantage Formulary ID: Version 6 Effective Date: 1/1/2016. PRODUCT(s) AFFECTED BRINTELLIX
BRINTELLIX BRINTELLIX Claim will pay automatically for brintellix if enrollee has a paid claim for at least a 1 days supply of any 2 generic formulary antidepressants in the past 365 days. Otherwise, brintellix
More informationRegulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: infliximab_remicade 5/2002 2/2017 2/2018 2/2017 Description of Procedure or Service Infliximab (REMICADE
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1017-7 Program Prior Authorization/Notification Medication Cimzia (certolizumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationGuide to the Modernized Reference Drug Program
Guide to the Modernized Reference Drug Program For prescribers and pharmacists Medical Beneficiary and Pharmaceutical Services Division June 1, 2016 Contents 1 Introduction 1 2 About this Guide 2 3 About
More informationCARE N CARE HEALTH PLAN
ARISTADA ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.6ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 662 MG/2.4ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 882
More informationCyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65
Market DC Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Cyltezo (adalimumab-adbm) 40 mg/0.8 ml prefilled syringe #* ^ Approval Duration 1 year
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 6 Last Review Date: December 8, 2017 Orencia Description Orencia (abatacept)
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationCARE N CARE HEALTH PLAN
ARISTADA Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882 MG/3.2ML Intramuscular Claim will pay automatically for
More informationSTEP THERAPY CRITERIA
STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription
More informationInfliximab/Infliximab-dyyb DRUG.00002
Infliximab/Infliximab-dyyb DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Inflectra (inflectra-dyyb) Approval Duration 1 year Comment Intravenous administration
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2017 P 3041-8 Program Step Therapy Medications UnitedHealthcare Pharmacy Clinical Pharmacy Programs *Orencia (abatacept) *This step criteria refers to the subcutaneous formulation of abatacept
More informationCIMZIA (certolizumab pegol)
CIMZIA (certolizumab pegol) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationPharmacy Management Drug Policy
SUBJECT: Cimzia (Certolizumab pegol) - for Ankylosing Spondylitis, Crohn s Disease, Psoriatic Arthritis and Rheumatoid Arthritis POLICY NUMBER: PHARMACY-07 EFFECTIVE DATE: 5/2009 LAST REVIEW DATE: 6/13/2018
More informationMarch 2017 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationRegulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 10 Last Review Date: June 22, 2017 Humira Description Humira (adalimumab),
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationNB Drug Plans Formulary Update
Bulletin #980 August 23, 2018 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective August 23, 2018. Included in this bulletin: Regular Benefit Additions Special
More informationDrugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
More informationInflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG CG-DRUG-64
Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG.00002 CG-DRUG-64 Override(s) Prior Authorization *Washington Medicaid See State Specific Mandates Medications Inflectra
More information2013 Step Therapy (ST) Criteria
2013 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationCorporate Medical Policy
Corporate Medical Policy Rituximab for the Treatment of Rheumatoid Arthritis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: rituximab_for_the_treatment_of_rheumatoid_arthritis 4/2008
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationHEALTHCARE EFFECTIVENESS DATA AND INFORMATION SET (HEDIS )
STARS MEASURES 2015 HEALTHCARE EFFECTIVENESS DATA AND INFORMATION SET (HEDIS ) Developed by the National Committee for Quality Assurance (NCQA), HEDIS is the most widely used set of performance measures
More informationRemicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subject: Infliximab Page: 1 of 13 Last Review Date: December 8, 2017 Infliximab Description Remicade
More informationDrug Therapy Guidelines
Simponi, Simponi Aria Applicable Medical Benefit x Effective: 2/13/18 Pharmacy- Formulary 1 x Next Review: 12/18 Pharmacy- Formulary 2 x Date of Origin: 7/2010 Pharmacy- Formulary 3/Exclusive x Review
More informationStep Therapy Criteria 2019
Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other CERTOLIZUMAB PEGOL CIMZIA 35554 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a patient with a diagnosis of moderate
More informationStep Therapy Approval Criteria
Effective Date: 10/01/2016 This document contains Step Therapy Approval Criteria for the following medications: 1. Colcrys (colchicine) 2. Cymbalta (duloxetine) 3. Dovonex (calcipotriene) 4. Enbrel (etanercept)
More informationXeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release)
Market DC Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release) Override(s) Prior Authorization Quantity Limit Medications Xeljanz (tofacitinib) Approval Duration 1 year Quantity Limit May be
More informationStep Therapy Approval Criteria
Effective Date: 07/01/2015 This document contains for the following medications: 1. Ambien CR (zolpidem ER) 2. Chantix Continuing Month (varenicline) 3. Chantix Starting Month (varenicline) 4. Cymbalta
More informationRegulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 14 Last Review Date: June 22, 2018 Humira Description Humira (adalimumab),
More information(tofacitinib) are met.
Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically
More informationo Your healthcare provider should test you for TB before starting CIMZIA.
Medication Guide CIMZIA (CIM-zee-uh) (certolizumab pegol) lyophilized powder or solution for subcutaneous use Read the Medication Guide that comes with CIMZIA before you start using it, and before each
More informationDrug Name (specify drug) Quantity Frequency Strength
Prior Authorization Form GEHA FEDERAL - STANDARD OPTION Autoimmune Conditions (FA-PA) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationAmjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65
Market DC Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2
More informationFml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 5 Report June 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationANTIDIABETIC AGENTS - MISCELLANEOUS
ANTIDIABETIC AGENTS - MISCELLANEOUS GLYXAMBI 10 MG-5 MG GLYXAMBI 25 MG-5 MG INVOKAMET 150 MG-1,000 MG INVOKAMET 150 MG-500 MG INVOKAMET 50 MG-1,000 MG INVOKAMET 50 MG-500 MG INVOKAMET XR 150 MG-1,000 MG,
More informationPPHP 2017 Formulary 2017 Step Therapy Criteria
ARISTADA Aristada Prefilled Syringe 1064 MG/3.9ML Intramuscular Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier National Quality Strategy Domain:
More informationCarelirst.+.V Family of health care plans
Carelirst.+.V Family of health care plans CVS Caremark POLICY Document for ACTEMRA The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific
More informationDrug Regimen Optimization
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Excluding Valsartan / Ramipril Prior authorization criteria logic: a description
More informationActemra. Actemra (tocilizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra
More informationTherapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol
Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has
More informationRegulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 13 Last Review Date: September 20, 2018 Humira Description Humira (adalimumab),
More informationRemicade (infliximab) DRUG.00002
Applicability/Effective Date *- Florida Healthy Kids Remicade (infliximab) DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Approval Duration 1 year Comment Intravenous
More informationSTEP THERAPY CRITERIA
STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription
More informationHumira (adalimumab) DRUG.00002
Humira (adalimumab) DRUG.00002 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Humira 10 mg/0.2 ml syringe Humira pediatric Crohn s Disease starter pack 40 mg/0.8 ml
More information3. Did the patient show evidence of remission by week 8 of Humira Y N therapy?
09/23/2015 Prior Authorization AETA BETTER HEALTH OF MICHIGA (MEDICAID) Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationMEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib)
MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) Read this Medication Guide before you start taking XELJANZ and each time you get a refill. There may be new information. This Medication Guide does not
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If
More informationUPMC for You Pharmacy and Therapeutics Committee Meeting April 8, 2013 meeting
UPMC for You Pharmacy and Therapeutics Committee Meeting April 8, 2013 meeting 1. Call to order: The meeting was called to order at 7:05 a.m. 2. Review of the minutes: The minutes of the January meeting
More informationANTIDIABETIC AGENTS - MISCELLANEOUS
ANTIDIABETIC AGENTS - MISCELLANEOUS Glyxambi 10 mg-5 mg tablet Glyxambi 25 mg-5 mg tablet Invokamet 150 mg-1,000 mg tablet Invokamet 150 mg-500 mg tablet Invokamet 50 mg-1,000 mg tablet Invokamet 50 mg-500
More informationActemra (tocilizumab) CG-DRUG-81
Market DC Actemra (tocilizumab) CG-DRUG-81 Override(s) Prior Authorization Approval Duration 1 year Medications Line of Business Quantity Limit Actemra (tocilizumab) vials VA MCD and All L-AGP May be subject
More informationSTEP THERAPY CRITERIA
STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription
More information